银杏二萜内酯葡胺联合依达拉奉右莰醇治疗急性缺血性脑卒中的效果  

Effects of Ginkgo diterpene lactone meglumine combined with Edaravone dextrocamphenol in acute ischemic stroke

作　　者：刘书娜 Liu Shu-na(Department of Neurology,Jinshui District General Hospital of Zhengzhou,Zhengzhou 453000,China)

机构地区：[1]郑州市金水区总医院神经内科,河南郑州453000

出　　处：《四川生理科学杂志》2025年第4期830-833,共4页

摘　　要：目的:探究急性缺血性脑卒中(Acute ischemic stroke,AIS)患者应用银杏二萜内酯葡胺(Ginkgo diterpene lactone meglumine,GDLM)联合依达拉奉右莰醇的治疗效果。方法:回顾性分析2022年11月至2024年1月期间本院收治的97例AIS患者的临床资料。对照组(n=48)静脉滴注依达拉奉右莰醇15mL治疗,实验组(n=49)在此基础上静脉滴注GDLM25 mg,治疗14 d后观察临床疗效和不良反应发生情况。并于治疗前、治疗14 d后分别采用简易精神状态量表(MiniMental State Inventory,MMSE)、卒中量表(National institutes of health stroke scale,NIHSS)、Barthel指数评估患者治疗前后病情变化,另采用酶联免疫法、光化学法检测血小板聚集率(Platelet aggregation,PAG)、血小板α颗粒膜糖蛋白(Alpha-granular membrane protein,CD62p)、血小板分子标志物(Procaspase activating compound,PAC)-1、白细胞介素-1β(Interleukin-1β,IL-1β)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)、IL-8、内皮型一氧化氮合酶(Endothelial nitric oxide synthase,eNOS)、可溶性细胞间黏附分子(Soluble Intercellular Adhesion Molecule-1,sICAM)-1水平。结果:实验组的临床治疗效果显著高于对照组(P<0.05)。实验组治疗后的MMSE、Barthel评分均较对照组显著提高,NIHSS评分较对照组显著降低(P<0.05)。治疗后,实验组CD62p、PAC-1、PAG水平均显著低于对照组(P<0.05)。与对照组相比,实验组治疗后的eNOS、VEGF水平均显著提高,IL-8、sICAM-1、IL-1β水平均显著降低(P<0.05)。两组的不良反应发生率无显著差异(P>0.05)。结论:GDLM联合依达拉奉右莰醇治疗,能改善AIS患者神经功能,抑制血小板聚集,缓解炎症反应及血管内皮损伤,且安全性较高。Objective:To investigate the therapeutic effect of Ginkgo diterpene lactone meglumine(GDLM)combined with edaravone dextrocamphenol in patients with acute ischemic stroke(AIS).Methods:Retrospective analysis of clinical data of 97 patients with AIS admitted to our hospital from November 2022 to January 2024.The control group(n=48)was treated with intravenous infusion of edaravone dextrocamphenol 15 mL,while the experimental group(n=49)was treated with intravenous infusion of GDLM 25 mg on this basis.After 14 days of treatment,the clinical efficacy and adverse reactions were observed.Before and after treatment,theMiniMental State Inventory(MMSE),National institutes of health stroke scale(NIHSS),and Barthel index were used to assess the changes in the patient's condition before and after treatment.In addition,enzyme-linked immunosorbent assay and photochemical methods were used to detect platelet aggregation(PAG),platelet alpha-granular membrane protein(CD62p),procaspase activating compound(PAC)-1,interleukin-1β(IL-1β),vascular endothelial growth factor(VVEGF),IL-8,endothelial nitric oxide synthase(eNOS),and soluble intercellular adhesion molecule-1(sICAM)-1 levels.Results:The clinical therapeutic effect of the experimental group was significantly higher than that of the control group(P<0.05).The scores of MMSE and Barthel in the experimental group after treatment were significantly higher than those in the control group,and the NIHSS score was significantly lower than that in the control group(P<0.05).After treatment,the levels of CD62p,PAC-1,and PAG in the experimental group were significantly lower than those in the control group(P<0.05).Compared with the control group,the levels of eNOS and VEGF in the experimental group after treatment were significantly increased,while the levels of IL-8,sICAM-1,and IL-1βwere significantly decreased(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:GDLM combined with edaravone dextrocamphenol can impro

关 键 词：银杏二萜内酯葡胺 依达拉奉右莰醇 急性缺血性脑卒中 血小板聚集功能 血管内皮细胞功能 

分 类 号：R743.3[医药卫生—神经病学与精神病学]